Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06610201 · ClinicalTrials.gov registry record
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
A clinical trial of Von Willebrand Disease (VWD) and Von Willebrand Disease (VWD), Type 1, sponsored by Hemab ApS.
- Recruiting
- Registry status
- 200
- Enrollment target
- 17
- Study locations
NCT06610201: Recruiting study of Von Willebrand Disease (VWD) and Von Willebrand Disease (VWD), Type 1, sponsored by Hemab ApS.
NCT06610201 is a study of Von Willebrand Disease (VWD) and Von Willebrand Disease (VWD), Type 1 that is actively recruiting participants, run by Hemab ApS. The registered enrollment target is 200 participants, above the 59-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (239% higher). The trial reports 17 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06610201, a study of Von Willebrand Disease (VWD) and Von Willebrand Disease (VWD), Type 1, is actively recruiting participants, sponsored by Hemab ApS.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)
Conditions Studied
Interventions
- OTHER Clinical outcomes of patients with VWD, Type 1
- OTHER Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3
Study Locations (17)
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- Children's Hospital of Los Angeles - Los Angeles
Florida
- University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center - Miami
Georgia
- Emory Children's Center - Atlanta
Indiana
- Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center - Indianapolis
Louisiana
- Tulane University School of Medicine - New Orleans
Michigan
- University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-08-30 |
| Est. Completion | 2026-06 |
What NCT06610201 shows while recruiting
NCT06610201 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 59-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (239% higher).
The record links to 7 conditions, with Von Willebrand Disease (VWD) appearing as the primary indexed condition, and to 2 interventions - of which Clinical outcomes of patients with VWD, Type 1 is the first listed.
NCT06610201 lists 17 locations in 17 states (Arizona, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT06610201 about?
NCT06610201 is a clinical study titled "A Study of Bleeding and Treatment in Participants With Von Willebrand Disease". The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a popul...
What is the current status of trial NCT06610201?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-08-30. Estimated completion is 2026-06.
What conditions does trial NCT06610201 study?
This clinical trial studies the following conditions: Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3, Von Willebrand Disease, Type 2A.
What interventions are being tested in trial NCT06610201?
The interventions under investigation include: Clinical outcomes of patients with VWD, Type 1 (OTHER), Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3 (OTHER).
Who is sponsoring clinical trial NCT06610201?
This trial is sponsored by Hemab ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06610201 being conducted?
This trial has 17 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Disease (VWD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
RECRUITING · Phase 3
-
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
RECRUITING · Phase 3
-
T-TAS® wS Method Comparison
COMPLETED
-
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI